Clinical trial · Interventional
Positron Emission Tomography in Monitoring Treatment Response in Women With Newly Diagnosed Breast Cancer
Monitoring Treatment Response in Women With Breast Cancer Utilizing FLT-PET/CT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will investigate the sensitivity and specificity of FLT-PET/CT in primary breast cancer detection and in the use of FLT-PET in monitoring how well a breast tumor respond to treatment. We will compare this technique with other imaging modalities as well as with tissue collection (during a biopsy). We will recruit women with a newly diagnosed invasive breast cancer, who are able to tolerate undergoing a PET/CT (possibly two scans) scan,
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adult Women With a New Diagnosis of Invasive Breast Cancer (Have Not Undergone Treatment) | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 3'-deoxy-3'-[18F]fluorothymidine | Other | — | UNRESOLVED |
| FLT-PET/CT | Radiation | — | UNRESOLVED |
| Positron Emission Tomography/computed tomography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Arm I
- description
- Patients undergoing definitive surgery after cancer diagnosis undergo 3'-deoxy-3'-\[18F\] fluorothymidine (FLT)-PET prior to definitive surgery. Patients undergoing neoadjuvant chemotherapy prior to definitive surgery undergo FLT-PET prior to and after completion of neoadjuvant chemotherapy
- interventionNames
- Other: 3'-deoxy-3'-[18F]fluorothymidine
- Procedure: Positron Emission Tomography/computed tomography
- Radiation: FLT-PET/CT
Primary outcomes (2)
- measure
- Sensitivity and specificity of FLT-PET comparing with standard FDG-PET
- measure
- Correlate SUV with % Ki67 nuclear stain
Secondary outcomes (2)
- measure
- Change in SUV with change in tumor proliferation index (%Ki67 nuclear stain) (when neoadjuvant therapy is used)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Breast biopsy positive for an invasive malignancy (core needle, mammatone, or incisional biopsy) * Participants must be planning to have surgery at the Hospital of the University of Pennsylvania * Participants must be able to tolerating lying on the table for about an hour * Newly diagnosed primary breast cancer, which is classified as being operable (T1-T4) Exclusion Criteria: * Pregnant women * History of severe renal disease * Prior history of breast cancer of the study breast within the last five years.
References
Publications (0)
Data not yet available